Trial Profile
A Phase 1, Single Ascending Dose Study of the Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs ALXN 1102 (Primary) ; ALXN 1102 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; First in man
- Sponsors Alexion AstraZeneca Rare Disease
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 21 May 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 05 Nov 2013 New trial record